Teva Pharmaceutical Industries Limited (TEVA)

Market Cap	18.74B
Revenue (ttm)	16.00B
Net Income (ttm)	-493.00M
Shares Out	1.13B
EPS (ttm)	-0.44
PE Ratio	n/a
Forward PE	5.59
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,673,523
Open	16.27
Previous Close	16.34
Day's Range	16.10 - 16.62
52-Week Range	7.42 - 17.69
Beta	0.91
Analysts	Strong Buy
Price Target	17.00 (+2.72%)
Earnings Date	Jul 31, 2024

About TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1901
• Employees: 37,851
• Stock Exchange: NYSE
• Ticker Symbol: TEVA

Financial Performance

In 2023, TEVA's revenue was $15.85 billion, an increase of 6.17% compared to the previous year's $14.93 billion. Losses were -$559.00 million, -77.15% less than in 2022.

Analyst Forecast

According to 8 analysts, the average rating for TEVA stock is "Strong Buy." The 12-month stock price forecast is $17.0, which is an increase of 2.72% from the latest price.

Price Target

$17.0

(2.72% upside)

Analyst Consensus: Strong Buy